Biomedicine and medical devices / Complete systems and use-case applications Supply-chain Study

Comparative structure study

The largest recorded reporting jurisdiction, Jiangsu, contains 196 records (14.3% of this 1,373-record cohort). The remaining cohort contains 1,177 records. The comparison concerns archive composition.

The recorded reporting jurisdiction label Shanghai accounts for 5.8% here (79/1,373), compared with 9.0% in the parent set (130/1,449), an absolute gap of 3.2 percentage points.

516/1,373 companies link to pages with existing source-supported excerpts (37.6% of the cohort). The other 857 records remain usable for archive composition, but do not support new operating case studies.

An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.

The parent set, Biomedicine and medical devices, contains 1,449 records. This cohort contributes 1,373 (94.8%); 76 records remain after excluding it.

The parent set, All public archive records, contains 19,297 records. This cohort contributes 1,373 (7.1%); 17,924 records remain after excluding it.

Ratio of label participation, not market share; multi-label counts overlap.

Excluding this cohort, the recorded reporting jurisdiction label Shanghai covers 51/76 remaining records (67.1%), an absolute gap of 61.4 percentage points from this cohort.

The full reporting jurisdiction distribution has 36 labels; the top 3 contain 481/1,373 records (35.0%).Other known labels contain 892 records.

For 1,373 records with known labels, the effective category count is 14.5, versus 36 actual labels. Definitions and scope are in the methodology.

The table shows ten labels; 26 others are included in the calculations above.

Record counts do not rank supply capability or economic size.

The largest intersection, Jiangsu × Biomedicine, contains 185 records, or 94.4% of the 196 records carrying the Jiangsu label.

A cell contains company IDs carrying both labels. It does not establish procurement, supply or investment relationships between firms. Multi-label cells may overlap.

This page displays 8 of the full cross-tab’s 86 non-empty cells; the other 78 remain in the analysis.

Non-empty fields are not necessarily accurate or supported by originals.

Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.

A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.

269 of this cohort’s 1,373 records link through existing company-ID mappings to 2026 lists from all jurisdictions (19.6%). This intersection measures list linkage, not successful recognition or company growth.

List rows and company IDs are separate counts, not new firms or final recognition.

Shared records with Biomedicine / Biomedicine and medical devices / Complete systems and use-case applications Supply-chain Study: 1,292; records in this cohort but outside that set: 81. The intersection/union ratio is 94.1%, a measure of label overlap rather than business collaboration. Read comparison

Shared records with Biomedicine / Biomedicine and medical devices / Complete systems and use-case applications Sub-industry and Supply-chain Study: 643; records in this cohort but outside that set: 730. The intersection/union ratio is 46.8%, a measure of label overlap rather than business collaboration. Read comparison

Stable-ID samples, not rankings; metrics use the full cohort.